RVMDW

• Pipeline progress: Continued advancement of 3 clinical stage RAS(ON) inhibitors. Daraxonrasib in pancreatic cancer has received 3 special designations. Clinical updates on daraxonrasib in pancreatic cancer including Phase I data, RASolute 302-304 trials. Elironrasib monotherapy data in G12C non-small cell lung cancer. RMC-5127 on track for first-in-human trial in Q1 2026. • Organizational appointments: Alan Sandler joined as Chief Development Officer; Alicia Gardner and Gerwin Winter in key commercial roles. • Financials: Ended Q3 2025 with $1.93B in cash and investments. R&D and G&A expenses increased. Projected full-year 2025 GAAP net loss between $1.03B and $1.09B.

• Reiterated 2025 financial guidance, expecting full-year 2025 GAAP net loss to be between $1.03 billion and $1.09 billion, including noncash stock-based compensation expense between $115 million and $130 million.

No detailed product segment financial performance with revenue contribution provided in the transcript.

No specific risks discussed beyond the standard forward-looking statement disclaimer noting actual results may differ from forward-looking statements.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.

Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?

A: Mark Goldsmith mentioned pride in receiving the voucher, stating it's for an oncology product and aims to accelerate review timelines but no specific difficulties anticipated.